Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

详细信息    查看全文

• 作者：Uwe Pelzer^a ; ^{uwe.pelzer@charite.de" rel="nofollow} ; Ingo Schwaner^b ; Jens Stieler^a ; Mathias Adler^c ; Jö ; rg Seraphin^d ; Bernd Dö ; rken^a ; Hanno Riess^a ; Helmut Oettle^a
• 关键词：Pancreatic cancer ; Gemcitabine ; Best supportive care ; Second-line
• 刊名：European Journal of Cancer
• 出版年：2011
• 出版时间：July 2011
• 年：2011
• 卷：47
• 期：11
• 页码：1676-1681
• 全文大小：367 K

文摘

Background

Gemcitabine usually given until progressive disease (PD) is the main first-line treatment option for patients with inoperable advanced pancreatic cancer (APC). Currently there is no accepted active regimen for second-line chemotherapy. Previous phase II studies suggest clinical relevant activity of oxaliplatin, folinic acid and 5-FU (OFF). We initiated a phase III multicentre study comparing OFF versus best supportive care (BSC) in patients with APC progressing while on gemcitabine therapy.

Methods

In this open randomized study, patients with CT and/or MRI confirmed progressive disease while on gemcitabine therapy were randomized 1:1 to OFF or BSC. Stratification included duration of first-line therapy (<3, 3 to 6 and >6 months), performance status (KPS 70–80%; 90–100%) and tumour stage (M1/M0). OFF consisted of folinic acid 200 mg/m² followed by 5-fluorouracil 2 g/m² (24 h) on d1, d8, d15, d22 and oxaliplatin 85 mg/m² on days 8 and 22. After a rest of 3 weeks the next cycle was started on d43. A total of 165 patients were calculated to demonstrate a doubling of survival time after progression on first-line therapy.

Results

After inclusion of forty six patients the trial was terminated according to predefined protocol regulations due to insufficient accrual (lack of acceptance of BSC by patients and physicians. Patient characteristics were well balanced between both study arms. The OFF regimen was well tolerated with more patients with grade I/II paraesthesia and grade II/III nausea/emesis and diarrhoea. Median second-line survival was 4.82 [95% Confidence Interval; 4.29–5.35] months for OFF treatment and 2.30 [95% CI; 1.76–2.83] months with BSC alone (0.45 [95% CI: 0.24–0.83], p = 0.008). Median overall survival for the sequence GEM-OFF was 9.09 [95% CI: 6.97–11.21] and 7.90 [95% CI: 4.95–10.84] months for GEM-BSC (0.50 [95% CI: 0.27–0.95], p = 0.031) respectively.

Interpretation

Although stopped prematurely, this randomized trial provides at first time evidence for the benefit of second-line chemotherapy as compared to BSC alone for patients with APC. OFF significantly prolonged survival time compared to BSC alone after failure of first-line therapy with gemcitabine.